Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have received a consensus rating of “Moderate Buy” from the fourteen brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $13.80.
A number of research analysts recently weighed in on IOVA shares. Citigroup reissued an “outperform” rating on shares of Iovance Biotherapeutics in a research note on Friday, August 7th. Zacks Research raised Iovance Biotherapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 26th. HC Wainwright increased their price target on Iovance Biotherapeutics from $9.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, September 29th. Citizens Jmp lifted their price target on shares of Iovance Biotherapeutics from $8.00 to $12.00 and gave the company a “market outperform” rating in a research report on Friday, November 6th. Finally, TD Cowen lifted their price target on shares of Iovance Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, August 24th.
View Our Latest Stock Analysis on Iovance Biotherapeutics
Hedge Funds Weigh In On Iovance Biotherapeutics
A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Iovance Biotherapeutics during the second quarter worth approximately $153,744,000. Palo Alto Investors LP bought a new position in Iovance Biotherapeutics during the second quarter worth $22,032,229. Bank of America Corp DE bought a new position in Iovance Biotherapeutics during the second quarter worth $20,773,000. Dimensional Fund Advisors LP raised its stake in Iovance Biotherapeutics by 71.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,645,702 shares of the biotechnology company’s stock valued at $9,282,000 after purchasing an additional 1,106,592 shares during the last quarter. Finally, Xcelsior Advisor Partners LLC raised its stake in Iovance Biotherapeutics by 3.2% during the 3rd quarter. Xcelsior Advisor Partners LLC now owns 1,841,485 shares of the biotechnology company’s stock valued at $27,291,000 after purchasing an additional 57,561 shares during the last quarter. 77.03% of the stock is currently owned by institutional investors.
Iovance Biotherapeutics Stock Performance
Shares of NASDAQ IOVA traded up $0.13 during mid-day trading on Friday, reaching $7.76. The company had a trading volume of 11,673,104 shares, compared to its average volume of 15,424,362. The stock has a fifty day moving average of $11.33 and a two-hundred day moving average of $6.10. The company has a market capitalization of $3.59 billion, a price-to-earnings ratio of -14.64 and a beta of 0.88. Iovance Biotherapeutics has a 12-month low of $2.08 and a 12-month high of $15.37.
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.04. The firm had revenue of $121.47 million for the quarter, compared to the consensus estimate of $115.98 million. Iovance Biotherapeutics had a negative net margin of 58.20% and a negative return on equity of 29.71%. Iovance Biotherapeutics’s revenue was up 64.8% compared to the same quarter last year. Sell-side analysts forecast that Iovance Biotherapeutics will post -0.41 earnings per share for the current fiscal year.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics is a biotechnology company focused on developing and commercializing personalized cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, which are expanded in a laboratory and returned to the patient. The company’s lead product, Amtagvi (lifileucel), is a TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma previously treated with specified therapies.
Featured Stories
- Five stocks we like better than Iovance Biotherapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
